Intrauterine intestinal obstruction in a preterm infant with severe mevalonate kinase deficiency - a case report.

Matern Health Neonatol Perinatol

Department of General Paediatrics, Neonatology and Paediatric Cardiology, Medical Faculty, University Hospital Duesseldorf, Heinrich Heine University, Moorenstraße 5, Duesseldorf, 40225, Germany.

Published: March 2025

Background: Mevalonate kinase deficiency is an inherited autoinflammatory disorder that can present with a wide clinical spectrum, ranging from mild forms with recurrent episodes of fever, lymphadenopathy, splenomegaly and skin rash to the much rarer severe form, which is characterized by additional occurrences of psychomotor impairment, cholestatic jaundice, ophthalmological symptoms, and failure to thrive. The few cases described with perinatal onset often showed a very severe clinical course.

Case Presentation: Here, we report the case of a preterm infant born at 30 + 2 weeks of gestation with a prenatal genetic diagnosis of mevalonate kinase deficiency presenting with intrauterine bowel dilatation, mild hydrops fetalis, and microcephaly. Laparotomy on the second day of life revealed intestinal obstruction necessitating partial ileum resection and ileostomy. The neonate had recurrent inflammatory reactions with elevated C-reactive protein levels, severe cholestasis, a progressive liver dysfunction, and an increasingly distended abdomen with subsequent respiratory insufficiency. Urinary mevalonic acid was highly elevated. The patient received anti-inflammatory therapy with prednisone and anakinra. Unfortunately, the patient died at the age of 77 days due to cardiorespiratory failure.

Conclusions: This case shows that intestinal obstruction with dilated fetal bowel loops can be an initially leading clinical symptom of severe mevalonate kinase deficiency. Diagnostics should be considered at an early stage, especially in the presence of other anomalies such as hydrops fetalis, growth restriction, or microcephaly. Data on the neonatal course of severe mevalonate kinase deficiency are still scarce and further studies are needed, particularly on treatment in neonates and young infants.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881282PMC
http://dx.doi.org/10.1186/s40748-025-00207-wDOI Listing

Publication Analysis

Top Keywords

mevalonate kinase
20
kinase deficiency
20
intestinal obstruction
12
severe mevalonate
12
preterm infant
8
hydrops fetalis
8
severe
6
mevalonate
5
kinase
5
deficiency
5

Similar Publications

Intrauterine intestinal obstruction in a preterm infant with severe mevalonate kinase deficiency - a case report.

Matern Health Neonatol Perinatol

March 2025

Department of General Paediatrics, Neonatology and Paediatric Cardiology, Medical Faculty, University Hospital Duesseldorf, Heinrich Heine University, Moorenstraße 5, Duesseldorf, 40225, Germany.

Background: Mevalonate kinase deficiency is an inherited autoinflammatory disorder that can present with a wide clinical spectrum, ranging from mild forms with recurrent episodes of fever, lymphadenopathy, splenomegaly and skin rash to the much rarer severe form, which is characterized by additional occurrences of psychomotor impairment, cholestatic jaundice, ophthalmological symptoms, and failure to thrive. The few cases described with perinatal onset often showed a very severe clinical course.

Case Presentation: Here, we report the case of a preterm infant born at 30 + 2 weeks of gestation with a prenatal genetic diagnosis of mevalonate kinase deficiency presenting with intrauterine bowel dilatation, mild hydrops fetalis, and microcephaly.

View Article and Find Full Text PDF

Cholesterol metabolism is abnormally active in tumour cells. Metabolic enzymes related to cholesterol metabolism are upregulated in tumours, but their nonmetabolic functions remain unclear. We found that MVK (mevalonate kinase) is upregulated in lung adenocarcinoma tissues vs.

View Article and Find Full Text PDF

Background: Anakinra is an interleukin-1 receptor antagonist (IL-1Ra). Since IL-1 has been shown to play a key role in the etiology of different autoinflammatory diseases, blocking its pathway has become an important therapeutic target, even in neonates.

Aims: We aimed to report our experience in using anakinra to treat specific neonatal inflammatory conditions.

View Article and Find Full Text PDF
Article Synopsis
  • Insufficient interferon response in tumor cells limits the effectiveness of immune checkpoint blockade (ICB) therapy, particularly in anti-PD-1 treatment for microsatellite instability (MSI) colorectal cancer (CRC).
  • Through screening, the study identified mevalonate kinase (MVK) as a key negative regulator of this interferon response in MSI CRC cells, where its genetic removal led to better immune cell infiltration and tumor growth suppression in mice.
  • The research highlighted that lowered MVK expression in human tumor samples associates with improved responses to anti-PD-1 therapy, indicating that targeting MVK could enhance ICB therapy by boosting interferon signaling in MSI CRC patients.
View Article and Find Full Text PDF

Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry.

Rheumatol Ther

February 2025

Division of Paediatric Rheumatology and Autoinflammation Reference Centre Tübingen, Department of Paediatrics, University Hospital Tübingen; Member of ERN-RITA, Tübingen, Germany.

Introduction: Interim analysis of the long-term safety and effectiveness of canakinumab, at a patient level, in the mevalonate kinase deficiency/hyperimmunoglobulin-D syndrome (MKD/HIDS) cohort of the RELIANCE registry.

Methods: From June 2018, the RELIANCE registry enrolled paediatric (aged ≥ 2 years) and adult patients (aged ≥ 18 years) with MKD/HIDS who were receiving canakinumab as part of their routine medical care. Safety, physician- and patient-reported measures of disease activity and dosing patterns were evaluated at baseline and every 6 months until end-of-study visit.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!